Actively Recruiting
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Led by The Affiliated Hospital of Qingdao University · Updated on 2024-08-09
18
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
CONDITIONS
Official Title
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosed with HPV-associated carcinomas
- At least one measurable lesion defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You will not qualify if you...
- Active or uncontrollable infections or major medical illnesses of the heart or lungs
- Active autoimmune diseases
- Known active Hepatitis B or Hepatitis C infection
- Other severe medical conditions limiting participation in the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The affiliated hosptial of qingdao university
Qingdao, Shandong, China, 266071
Actively Recruiting
Research Team
H
Hongying Lv
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here